Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...
An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...
The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...
King's College London (KCL) has announced the development of a "game-changer" injection it says is the first new treatment for asthma attacks in more than half a century. Working with the University ...
· Approximately 1.7 million people in the UK are living with chronic obstructive pulmonary disease (COPD) with around 600,000 being unaware of it (undiagnosed)1 · COPD has strong links with ...
Almost 300,000 people with asthma in the UK who were deemed at increased risk from Covid-19 failed to receive their first vaccine dose on time, new estimates show. Severe asthma sufferers were added ...
An ‘asthma bus’ officially opened today at Chorley House, based on Lancashire Enterprise Business Park in Leyland, as it begins its journey around the UK aiming to offer vitally needed support to ...
A NEW injection to treat patients who don’t respond to conventional asthma medication has been approved on the NHS. The National Institute for Health and Care Excellence (Nice) has recommended ‘wonder ...
The National Institute for Health and Care Excellence (Nice) has recommended dupilumab for some patients whose asthma does not respond to conventional treatments. Asthma UK and the British Lung ...
Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback